CA-CODED-AGENCY
14.4.2021 16:02:07 CEST | Business Wire | Press release
Global modern communications company Coded Agency today announces a highly-anticipated, strategic overhaul of its branding and website following steady growth and innovation into new markets and industries.
Coded Agency, formerly known as codedpr, was founded in 2015 and quickly grew to become a leading agency of record for a range of lifestyle, fashion, beauty, fitness and wellness brands. In 2020, the agency generated a net income increase of 35%, despite an unprecedented global pandemic. Its upward trajectory continues in 2021 with not only a 65% increase in revenue in Q1 and a 50% increase in clients between Q1 and Q2, but a bold, fresh new look, instrumental employee promotions and expansion into Europe with the agency founder’s relocation to France.
The minority-owned, female-founded company renews its namesake as Coded Agency in tandem with a new website and branding designed by Designsake Studio, a San Francisco-based, award-winning and female founded design firm. “Coded Agency gets what it takes to build and support modern brands and we’re proud of our partnership with this women-owned and operated agency,” said Danielle McWaters, Founder & CCO of Designsake Studio.
Reflecting expansion into a more modern approach to communications that extends beyond traditional public relations and standard influencer programming, the new branding and positioning underscores the agency’s abilities to meet the evolving needs of its clients in a fast-changing world. The new website highlights the agency’s broad range of services including PR, influencer and celebrity marketing, event activations, partnerships and endorsements.
“Our goal for the redesign was to create a new brand identity that enhanced the visitor’s digital experience and showcased the results they deliver for their clients,” McWaters explained. “A fresh color palette, eye-catching typography and monochromatic photography communicate the agency’s tailored, edgy and purposeful approach to communications strategy,” McWaters continued.
Coded Agency prides itself on working with purposeful brands that embrace diversity, sustainability, inclusivity and female empowerment, aiming to amplify their stories. Most recently, Coded Agency has partnered with MVMT , premium watches and accessories; Scentbird , luxury fragrance subscription service; and niLuu , sustainably-made, PETA-approved vegan silk loungewear and sleep accessories, among other client wins. In addition, the agency is honored to continue ongoing partnerships with loyal clientele: Alleyoop , beauty and lifestyle brand; Vitality Institute , renowned beauty and wellness brand known for its chemical peel and medical-grade skincare products; and Caleres brands Allen Edmonds, Naturalizer and Blowfish Malibu.
“To meet the agency’s ongoing plans for growth, we have expanded key roles internally and are establishing a global presence with full-time team members located in Los Angeles, New York and France,” said Jennifer Wentzo, Coded Agency’s Founder and CEO. “Synergistic alignment with companies such as our existing client base and partners like Designsake Studio is part of our DNA. We are proud of our redesign and hope it reflects our forward-thinking approach to modern communications.”
Recent promotions include Jules Barker, appointed Vice President from Senior Director, and Jamie Hecht, named New York PR Manager from Senior Account Executive. In their new roles, they will manage agency operations, continue to foster team development, oversee the agency’s diverse client roster and spearhead the agency’s business development and East Coast representation, respectively.
About Coded Agency
Founded in 2015, Coded Agency is a modern, full-service marketing communications agency situated at the intersection of strategy, instinct and hustle. From dynamic startups to legacy brands under publicly traded parent companies in a diverse range of industries, the agency team delivers impactful, meaningful campaigns that help its brands grow. Consistently topping seven figures in annual revenue since 2016, the team dreams about what’s on the horizon while keeping an eye on the bottom line and infuses their work with the passion and dedication that is singular to the entrepreneurial spirit. For more information, visit www.codedagency.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom